GlassScriptPhysician profile
Levi J Novero
NPI 1841485612
$3,239.42
in general payments reported to CMS, 2019-2025
25 companies · $483 in 2025
The $483 reported for 2025 was more than what a typical Pediatric Cardiology provider received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $602 · 2020: $65.67 · 2021: $653 · 2022: $423 · 2023: $515 · 2024: $498 · 2025: $483.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,496.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,495.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $880.58 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $769.75 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $244.64 | 2021 | |
| Glaxosmithkline, LLC. | $227.10 | 2022-2024 | Arexvy |
| Novo Nordisk INC | $170.67 | 2022-2025 | Wegovy |
| Csl Behring | $139.63 | 2021-2023 | Hemgenix |
| Actelion Pharmaceuticals US, INC. | $124.99 | 2023 | Uptravi, Opsumit |
| Eisai INC. | $83.83 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $68.24 | 2023-2025 | Dupixent, Evkeeza |
| Neurelis, INC. | $62.41 | 2020-2022 | |
| Sobi, INC | $62.17 | 2021-2022 | |
| Ucb, INC. | $48.94 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $48.04 | 2023-2025 | Bylvay |
| Arthrex, INC. | $45.00 | 2019 | |
| Azurity Pharmaceuticals, INC. | $42.88 | 2025 | Katerzia |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $33.27 | 2023-2024 | M-M-R II, Vaxelis, Gardasil 9 |
| Kiniksa Pharmaceuticals International, Plc | $26.75 | 2024 | Arcalyst |
| Zogenix INC. | $24.13 | 2021 | |
| Mauna Kea Technologies, INC. | $24.05 | 2025 | |
| Sanofi Pasteur INC. | $21.15 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.00 | 2020 | |
| Cranial Technologies, INC | $19.82 | 2024 | Doc Band |
| Alexion Pharmaceuticals, INC. | $18.76 | 2019 | |
| Pierre Fabre Pharmaceuticals, INC. | $17.86 | 2020 | |
| Ironshore Pharmaceuticals INC. | $13.76 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Levi Novero listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.